Lynparza Tablet (Olaparib) Regulatory Post-Marketing Surveillance
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
- Focus Adverse reactions
- Acronyms OLAP
- Sponsors AstraZeneca
- 22 Apr 2024 Planned End Date changed from 31 Dec 2024 to 30 Jun 2025.
- 22 Apr 2024 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2025.
- 18 Nov 2021 Planned number of patients changed from 600 to 650.